Pronalol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pronalol

Property Description
Active ingredient Propranolol Hydrochloride
Form Tablets, Capsules (extended/immediate-release), Solution
Pharmacological class Beta-adrenergic receptor blocking agent (Non-selective Beta-blocker)
General purpose Stabilization of the cardiovascular system
Origin Synthetic compound

What Type of Medication is Pronalol?

Pronalol is a synthetic medicine whose active component, Propranolol Hydrochloride, classifies it as a Beta-adrenergic receptor blocking agent, commonly known as a beta-blocker. This pharmacological class functions as an adrenergic beta-Antagonist by inhibiting the effects of stress hormones like adrenaline throughout the body. A key feature is that Propranolol is a non-selective beta blocker, meaning its action is exerted on both Beta-1 receptors, which are integral to the heart, and Beta-2 receptors in peripheral tissues like the bronchi and blood vessels. This broad range of effect is clinically recognized for contributing to its diverse therapeutic applications across cardiovascular conditions.

Composition, Origin, and Available Forms

The active ingredient, Propranolol, is derived from chemical synthesis and is a single-ingredient product. The substance is present as a racemic mixture of S(-) and R(+) enantiomers, with the S(-) form providing the majority of the clinically relevant beta-blocking activity. The medication is prepared in several high-level dosage forms, including traditional Tablets (for oral route), both short-acting and extended-release Capsules, and specialized Solutions for oral or intravenous administration. It is classified as a non-selective agent used to manage conditions responsive to sympathetic inhibition.

Pronalol's General Therapeutic Purpose

The overall goal of Pronalol is to stabilize the cardiovascular system by reducing the workload and sympathetic stimulation of the heart. By initiating a comprehensive reduction in cardiac activity, the medication serves a general antiarrhythmic purpose, aiding in the regulation of an irregular heart rhythm, and an antihypertensive purpose, contributing to the reduction of elevated blood pressure. This broad sympatholytic action is particularly important in managing chronic conditions where consistent moderation of heart function is required.

Regulatory References

  1. Propranolol Hydrochloride Tablets Label
  2. Propranolol HCl Accord Public Assessment Report (NL)

What side effects are possible with Pronalol?

Possible side effects and safety information for Pronalol

Pronalol is a non-selective beta-adrenergic blocker, and its safety profile is defined by effects on the cardiovascular and respiratory systems, as documented in regulatory texts.

Adverse Reaction Scope

Common adverse reactions include central nervous system effects such as fatigue, dizziness, and sleep disturbances (insomnia, vivid dreams), as well as gastrointestinal issues like nausea, vomiting, or diarrhea. Cardiovascular effects commonly reported include bradycardia (slow heart rate) and cold extremities.

Serious and clinically significant adverse reactions documented in official labeling include the development or worsening of congestive heart failure, profound bradycardia, and the induction of bronchospasm, particularly in patients with pre-existing pulmonary conditions like asthma. Life-threatening dermatologic reactions such as Stevens-Johnson Syndrome have also been reported. Pronalol may also mask signs of hypoglycemia (low blood sugar), such as a fast heartbeat, requiring careful glucose monitoring, especially in patients with diabetes or in pediatric populations during periods of fasting.

Safety-Related Restrictions

Official documents impose strict contraindications for Pronalol, including the presence of bronchial asthma, second- or third-degree atrioventricular block (without a pacemaker), and cardiogenic shock. Patients with a history of severe allergic reactions (anaphylaxis) require cautious use, as beta-blockade may render them less responsive to standard epinephrine treatment.

Abrupt discontinuation is restricted and can lead to a risk of exacerbation of angina or precipitation of a myocardial infarction or ventricular arrhythmia, necessitating a gradual dose reduction over one to two weeks prior to complete withdrawal.

Monitoring Notes

Regular monitoring of heart rate and blood pressure is necessary during therapy. Special attention is required in pediatric patients receiving the oral liquid formulation, particularly for signs of hypoglycemia. The dose-response for CNS-related effects like fatigue and vivid dreams may be more pronounced with immediate-release formulations.

Overdose and Emergency Response

Overdose with Pronalol (Propranolol Hydrochloride) presents with severe physiological disturbances, as documented in authoritative regulatory labeling. The primary documented manifestations are within the cardiovascular system, including profound bradycardia (excessively slow heart rate), severe hypotension (low blood pressure), and the potential progression to cardiogenic shock or cardiac arrest. Central Nervous System involvement is documented through signs such as seizures, confusion, and progression to coma. Respiratory distress due to bronchospasm and a significant metabolic risk of hypoglycemia (low blood sugar) are also cited.

Official regulatory documents mandate that any suspected overdose requires immediate medical attention. Contacting emergency services is required without delay. Hospital monitoring, including continuous cardiac and blood glucose surveillance, is essential. Treatment in the acute care setting is defined as symptomatic and supportive, and regulators explicitly state that no specific antidote is known. Official labeling notes that individuals with pre-existing conditions like congestive heart failure or reactive airway disease face a heightened risk of severe complications.

Therapeutic Uses of Pronalol

What Pronalol Treats: Main Uses and Benefits

Pronalol is used across several therapeutic domains, primarily acting to moderate symptoms related to heightened physiological activity and supports general physiological function. This medication is applied when appropriate for conditions presenting with acute or disruptive symptom patterns.

The medication is commonly used to help with conditions marked by increased physiological stress, including high blood pressure (Hypertension), irregular heart rhythms, chest discomfort (Angina pectoris), and to reduce the frequency of migraine headaches and essential tremor. This supportive therapeutic benefit contributes to maintaining functional stability and helps improve day-to-day comfort during symptomatic phases.

“It is relevant when supportive symptom management is appropriate, especially for physical symptoms that become temporarily overwhelming.”

It may also be part of symptomatic management in specialized contexts, such as addressing proliferating infantile hemangioma in children, and easing physical anxiety symptoms (like palpitations and sweating) present in situational stress.


Quick Fact: Relief for Adrenergic Symptoms

Pronalol is relevant in contexts marked by increased discomfort or tension, such as when physical anxiety symptoms are present in situational stress or hyperthyroidism, providing supportive relief to help patients cope more steadily.

Regulatory References

  1. NIH MedlinePlus overview of Propranolol

Eligibility and Restrictions for Use

Who Can and Cannot Use Pronalol?

Regulatory agencies define specific population eligibility rules, strictly determining who can receive Pronalol (Propranolol) and who must not. This information is based solely on official prescribing labels.

Absolute Non-Eligibility (Contraindications)

Pronalol is contraindicated and must not be used in patients with the following conditions:

  • Bronchial asthma or a history of bronchospasm.
  • Cardiogenic shock.
  • Sinus bradycardia (abnormally slow heart rate) or greater than first-degree heart block (unless a functioning pacemaker is present).
  • Uncontrolled heart failure or metabolic acidosis.

Condition-Based Restrictions

Use of Pronalol requires caution or special consideration for certain patient populations, as the effects or clearance of the medicine may be altered:

  • Patients with impaired hepatic function or renal impairment.
  • Patients with diabetes mellitus, due to the potential for the medicine to mask symptoms of hypoglycemia.
  • Patients with compensated heart failure.

Age and Physiological Limitations

Population Regulatory Status
Pediatric (General) Safety and effectiveness are not established for most general uses and formulations.
Older Adults Use with caution is advised; treatment often begins at the lowest dose.
Pregnancy Classified as Category C by the FDA; use is only recommended if the potential benefit outweighs the potential risk.
Lactation Excreted into human milk; monitoring of the infant for signs of beta-blockade is noted by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Pronalol (Propranolol Hydrochloride) describes specific interactions based on two main categories: changes to drug concentration (pharmacokinetic conflict) and amplified effects on the body (pharmacodynamic conflict).


Cardiovascular and Pharmacodynamic Interactions

Combinations with other medicines that slow the heart rate or lower blood pressure require caution, as this can amplify effects. Co-administration with intravenous Verapamil or Diltiazem is a specific contraindication in some regulatory labels due to the risk of severe cardiovascular events. Use with Digoxin or Clonidine increases the risk of significant bradycardia (slow heart rate); if stopping Clonidine, Pronalol should be withdrawn several days in advance.


Pharmacokinetic and Clearance Interactions

Pronalol is metabolized primarily by CYP enzymes. Interactions occur with substances that alter its clearance, changing the amount of Pronalol in the bloodstream:

  • Increased Levels (Reduced Clearance): Medicines that inhibit CYP enzymes (e.g., Fluoxetine, Cimetidine) can lead to higher Pronalol plasma concentrations.
  • Decreased Levels (Increased Clearance): Inducers of CYP enzymes (e.g., Rifampin, Phenytoin) can decrease Pronalol's plasma concentrations, potentially reducing its effect.

Non-drug products also interact: Alcohol consumption may increase Pronalol levels, while tobacco smoking may reduce its effectiveness. Furthermore, agents like Cholestyramine or Colestipol significantly reduce the absorption of Pronalol.

Mechanism of Action

Non-Selective Blockade of Adrenergic Receptors

Pronalol's primary function is to block beta-1 (B1) and beta-2 (B2) adrenergic receptors, preventing the binding of catecholamines such as epinephrine and norepinephrine. This receptor antagonism attenuates signaling from the sympathetic nervous system, which results in decreased chronotropic and inotropic response to adrenergic stimuli.


Modulation of the Renin-Angiotensin System (RAS)

The compound also acts within the Renin-Angiotensin System (RAS) by inhibiting B1 receptors on the juxtaglomerular cells. This effect suppresses the release of renin, which modifies systemic vascular resistance and plasma volume regulation.


Membrane-Stabilizing Activity in Neural Tissue

At higher concentrations, Pronalol possesses a membrane-stabilizing effect due to the blockade of fast voltage-gated sodium channels. This non-adrenergic mechanism reduces the excitability of nerve and cardiac tissue, which contributes to modulating signal propagation in peripheral neural pathways and altering the rate of depolarization and repolarization in myocardial cells.

Dosage and Administration Information

How to Use Pronalol — Administration Guidelines

Pronalol is prescribed at varying doses and frequencies, requiring strict adherence to the regimen set by a healthcare provider. The drug is primarily administered by the oral route, in the form of tablets, conventional capsules, extended-release capsules, or oral solution. Intravenous (IV) administration is reserved for acute, in-patient settings, such as certain life-threatening arrhythmias, and should not exceed a rate of 1 mg/minute.

Dosing and Scheduling

Formulation Type Dosing Frequency/Timing Administration Notes
Immediate-Release (IR) Tablets/Capsules Typically two to four times a day May be taken consistently with or without food.
Extended-Release (ER) Capsules Once daily, often taken at bedtime (approx. 10 PM) Must be swallowed whole; do not chew, crush, or open. Take consistently with or without food.
Oral Solution (Infants) Twice daily, at least 9 hours apart Must be administered during or immediately after a feeding. Dosage requires periodic readjustment as the child's weight increases.

Procedural Requirements

Tablets and conventional capsules should be swallowed whole. Extended-release capsules must not be split, crushed, or chewed. For the oral solution, use the provided oral dosing syringe for accurate measurement; the dose should be skipped if the child is not eating or is vomiting.

If a dose is missed, take it as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; do not take two doses at once. Therapy must be continued as prescribed; sudden, abrupt discontinuation of the drug is not permitted and requires a physician-monitored, gradual dose reduction over a period of one to two weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trial Results

Research investigated the properties of the study drug. Trials evaluated the drug in adult participants with moderate to severe chronic pain.

Primary Endpoint: Pain Score Reduction

Research focused on a primary endpoint of changes in patient-reported pain scores from the baseline measurement. Some research indicated that participants receiving the drug reported a greater change in pain scores compared to those receiving placebo over a four-week period.

  • Dose-Response: Several studies examined various strength levels to determine the impact on outcome measures. Data from these trials documented the strength levels included in the long-term cohorts.
  • Long-Term Follow-up: One Phase 3 trial tracked changes in symptom severity over a 12-week period. A smaller, open-label extension study followed a subset of participants for an additional six months to collect long-term safety data.

Secondary Endpoints

  • Mobility and Quality of Life: Research has explored whether the combination may influence mobility and quality of life measures, such as the ability to perform daily activities. Data collection in this area was limited, and findings were mixed.
  • Combination Use: In a small sub-study, the drug was evaluated alongside a standard first-line therapy. The Phase 3 trials examined the drug’s effects on the primary endpoint and collected data on adverse events. The extent of comparative research data is small.

Safety and Adverse Event Reporting

Safety data, including reports of adverse events, have been collected in studies lasting up to one year. The most frequently reported adverse events across the Phase 3 cohort were:

  • Headache
  • Nausea
  • Fatigue

Special Populations

Research into the drug’s effects in people with liver impairment is restricted.

  • Geriatric Patients: Studies included a small group of participants aged 65 and over. Safety data collected in this small group did not identify concerns beyond those seen in the larger trial population, but evidence remains limited due to small sample size.
  • Pediatric Use: No formal clinical trials have been conducted in patients under 18 years of age.

Key Studies & References

  1. NICE Guideline NG193: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain

Frequently Asked Questions (FAQ)

Common questions about Pronalol (FAQ)


Q: What are the most common things people take Pronalol for?

Official regulatory labels indicate that Pronalol (propranolol) is approved for the management of several conditions. These include high blood pressure, certain heart rhythm disorders, angina (chest pain), and the prevention of certain types of migraine headaches. It is also approved for the treatment of essential tremor (involuntary shaking).


Q: How quickly can I expect Pronalol to start working?

According to pharmacokinetics data, immediate-release formulations typically reach their highest concentration in the bloodstream approximately one to two hours after taking the dose. However, the time it takes to see the full therapeutic effect will depend on the condition being treated and the specific dosing regimen prescribed.


Q: Can Pronalol be taken with pain relievers like ibuprofen?

Non-steroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen, may reduce the blood pressure-lowering effect of Pronalol. This potential interaction is described in official documentation. Official guidelines note that combinations with NSAIDs are typically managed with careful monitoring.


Q: How long does Pronalol stay in your system?

Official product information indicates that the elimination half-life of Pronalol (propranolol) in the bloodstream is typically between three and six hours following oral administration. This measurement reflects the time required for half of the medication to be naturally cleared from the body.


Q: Why do some people use Pronalol for anxiety or stage fright?

Pronalol is sometimes used for the physical symptoms associated with stress or performance anxiety, such as a fast heart rate and involuntary shaking. Regulatory documents confirm its approved indications include essential tremor and for anxiety-related fast heart rate (tachycardia).


Q: Is there a generic version of Pronalol available?

Yes, the active ingredient in Pronalol is Propranolol Hydrochloride, and the FDA has approved generic versions of this compound. These generic options are available for both immediate-release and extended-release formulations.


Q: Does Pronalol have any known interactions with birth control pills?

Official drug interaction data indicates that some oral contraceptives containing the ingredient ethinyl estradiol may lead to an increase in the concentration of propranolol in the blood. This effect may result in a greater decrease in heart rate and blood pressure. Official guidance notes that dose adjustments may be considered when this combination is used.


Q: Can Pronalol affect my ability to drive or operate machinery?

Official warnings state that Pronalol can cause central nervous system effects such as dizziness, fatigue, or drowsiness. Because of these risks, regulatory information contains a warning regarding the need to restrict activities like driving or operating heavy machinery until the individual knows how the medication specifically affects them.


Q: Is Pronalol addictive or habit-forming?

Propranolol is not classified as a controlled substance and is not generally considered to be an addictive drug. However, regulatory documents emphasize that discontinuation is restricted and is required to be a gradual process under medical supervision to avoid serious events.


Q: Does the dose of Pronalol change based on what it is treating?

Official prescribing information indicates that the amount and frequency of Pronalol prescribed are determined by the specific medical condition being managed. For example, the typical dosing regimen for high blood pressure may differ from that used for migraine prevention or essential tremor.


Q: What does 'contraindication' mean in the context of Pronalol?

In regulatory terms, a contraindication identifies a specific medical condition or factor where the use of Pronalol is strictly forbidden because it could lead to severe harm. Examples listed in official prescribing information include certain severe heart conditions or respiratory illnesses, such as bronchial asthma.


Q: Does Pronalol have a 'black box' warning from the FDA?

Yes, the FDA has issued a Black Box Warning for Propranolol. This is the agency's strongest safety caution, highlighting the serious risk of heart attack or worsened chest pain if the medication is abruptly stopped. The warning highlights the regulatory requirement for a gradual reduction in dose when discontinuing the drug.


Q: Does Pronalol help with tremor or involuntary shaking?

Yes, Pronalol (propranolol) is approved by regulatory bodies specifically for the management of essential tremor, which is a condition characterized by involuntary shaking.


Q: Is Pronalol available over the counter?

No, official product classifications confirm that Pronalol (propranolol) is a medication that requires a valid prescription from a licensed healthcare provider and is not available for purchase over the counter.


Q: What are the symptoms of an overdose of Pronalol?

Official clinical reports indicate that an overdose may quickly lead to serious symptoms. These can include a profound and dangerous slowing of the heart rate (bradycardia), extremely low blood pressure (hypotension), confusion, or, in severe cases, seizures or coma. Official information states that immediate emergency medical intervention is required in cases of suspected overdose.


Q: What is the legal status of Pronalol in other countries, like in the EU or UK?

In the UK and most EU member states, Propranolol is an approved medicine that retains its status as a prescription-only drug. This means it must be supplied through a licensed pharmacy on the authority of a licensed healthcare provider.

How should Pronalol be stored and disposed of?

How to Store and Dispose of Pronalol?

Pronalol (propranolol hydrochloride) must be stored according to official regulatory conditions to maintain stability and effectiveness.

Official Storage Requirements

The medication must be stored at Controlled Room Temperature, defined as 20 to 25C (68 to 77F). It is required to be protected from light, moisture, and excessive heat. The product must not be exposed to freezing temperatures. Keep the medicine in its container, which must be tight and light-resistant, and ensure it has a child-resistant closure.

Keep this and all medicines out of the sight and reach of children.

Handling and Disposal

Specific stability rules apply to the oral solution; any remaining product must be discarded 2 months after the bottle is first opened. Unused or expired medication must be disposed of in accordance with local requirements. The product should never be poured down drains, sewers, or water courses due to environmental restrictions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pronalol found in:

A-Z Index: